Syndax Pharmaceuticals, Inc. (SNDX) financial statements (2021 and earlier)

Company profile

Business Address 35 GATEHOUSE DRIVE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments60728193819098
Cash and cash equivalents25312758342732
Short-term investments35425435476366
Restricted cash and investments 000000
Receivables0000000
Prepaid expense1111133
Deposits current assets1133121
Other undisclosed current assets0011112
Total current assets:627586988396105
Noncurrent Assets
Operating lease, right-of-use asset11  
Property, plant and equipment0000000
Other noncurrent assets0000000
Other undisclosed noncurrent assets  11   
Total noncurrent assets:1222111
TOTAL ASSETS:647687998496105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities101057568
Accounts payable6724135
Accrued liabilities1111111
Employee-related liabilities3221322
Deferred revenue22  
Debt00     
Contract with customer, liability22222
Other undisclosed current liabilities7611710910
Total current liabilities:18181716161719
Noncurrent Liabilities
Long-term debt and lease obligation01     
Operating lease, liability01  
Liabilities, other than long-term debt13141414151516
Deferred revenue1314  
Contract with customer, liability1414151515
Other liabilities0000000
Other undisclosed noncurrent liabilities  11   
Total noncurrent liabilities:14141515151516
Total liabilities:32323231313235
Stockholders' equity
Stockholders' equity attributable to parent32445569536470
Common stock0000000
Additional paid in capital527525524522492485474
Accumulated other comprehensive income (loss) 000(0)(0)(0)
Accumulated deficit(495)(481)(469)(454)(439)(421)(403)
Total stockholders' equity:32445569536470
TOTAL LIABILITIES AND EQUITY:647687998496105

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0000000
Operating expenses(15)(14)(16)(15)(20)(18)(19)
Operating loss:(14)(13)(15)(15)(19)(18)(19)
Nonoperating income0001011
Other nonoperating income (expense)(0)(0)(0)0(0)00
Net loss available to common stockholders, diluted:(14)(13)(15)(14)(19)(17)(18)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(14)(13)(15)(14)(19)(17)(18)
Comprehensive loss:(14)(13)(15)(14)(19)(17)(18)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)(0)00000
Comprehensive loss, net of tax, attributable to parent:(14)(13)(15)(14)(19)(17)(18)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: